Invivoscribe - Improving Lives with Precision Diagnostics®

INDUSTRY PIONEERS

Improving Lives with Precision Diagnostics^®

Invivoscribe is an industry pioneer with over 20 years of experience developing and manufacturing diagnostic products and reagents for leukemias and lymphomas. All of our diagnostic tests generate meaningful results allowing healthcare providers to confirm or modify treatment for each patient.

PRODUCTS

Best in class assays and reagents

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

LEARN MORE ⟶

CLINICAL LAB SERVICES

LabPMM offers clinical services with global reach

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally harmonized testing of novel and proprietary biomarkers that are critically important for patient care.

LEARN MORE ⟶

Invivoscribe-Parnterships-Category-Image-003

PARTNERSHIPS

CDx Turn-Key Collaboration

Invivoscribe provides a proven strategy to accelerate drug approvals, offering Product Development, Manufacturing, Clinical Lab Services and Global Regulatory Expertise.

LEARN MORE ⟶

INDUSTRY PIONEERS

Improving Lives with Precision Diagnostics^®

Invivoscribe is an industry pioneer with over 20 years of experience developing and manufacturing diagnostic products and reagents for leukemias and lymphomas. All of our diagnostic tests generate meaningful results allowing healthcare providers to confirm or modify treatment for each patient.

PRODUCTS

Best in class assays and reagents

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

LEARN MORE ⟶

CLINICAL LAB SERVICES

LabPMM offers clinical services with global reach

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally harmonized testing of novel and proprietary biomarkers that are critically important for patient care.

LEARN MORE ⟶

PARTNERSHIPS

CDx Turn-Key Collaboration

Invivoscribe provides a proven strategy to accelerate drug approvals, offering Product Development, Manufacturing, Clinical Lab Services and Global Regulatory Expertise.

LEARN MORE ⟶

CONNECT

Invivoscribe Newsroom

The Latest Publications, News, Articles and Press Releases

European Commission Approves Astellas’ XOSPATA™ for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe’s LeukoStrat® CDx FLT3 Mutation Assay

admin2019-10-30T17:00:23+00:00October 30th, 2019|Press Releases|

NOW AVAILABLE! MRD solutions for B- and T-cell clonality tracking

admin2019-09-23T22:05:58+00:00August 26th, 2019|Product Releases|

Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA

admin2019-07-04T21:08:52+00:00June 19th, 2019|Press Releases|

Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies

admin2019-07-04T21:09:04+00:00May 21st, 2019|Press Releases|

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

admin2019-09-24T18:21:23+00:00March 21st, 2019|Featured Publications, Publications|

ALL RELATED ARTICLES ⟶

CONNECT

Invivoscribe Newsroom

The Latest Publications, News, Articles
and Press Releases

European Commission Approves Astellas’ XOSPATA™ for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe’s LeukoStrat® CDx FLT3 Mutation Assay

admin2019-10-30T17:00:23+00:00October 30th, 2019|Press Releases|

NOW AVAILABLE! MRD solutions for B- and T-cell clonality tracking

admin2019-09-23T22:05:58+00:00August 26th, 2019|Product Releases|

Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA

admin2019-07-04T21:08:52+00:00June 19th, 2019|Press Releases|

Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies

admin2019-07-04T21:09:04+00:00May 21st, 2019|Press Releases|

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

admin2019-09-24T18:21:23+00:00March 21st, 2019|Featured Publications, Publications|

ALL RELATED ARTICLES ⟶

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Browse our comprehensive menu of product & testing services.

A proven strategy to acceleratedrug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 21st, 2019 Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

August 25th, 2018 A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 22nd, 2018 Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

INDUSTRY PIONEERS

Improving Lives with Precision Diagnostics®

PRODUCTS

Best in class assays and reagents

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

CLINICAL LAB SERVICES

LabPMM offers clinical services with global reach

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally harmonized testing of novel and proprietary biomarkers that are critically important for patient care.

PARTNERSHIPS

CDx Turn-Key Collaboration

Invivoscribe provides a proven strategy to accelerate drug approvals, offering Product Development, Manufacturing, Clinical Lab Services and Global Regulatory Expertise.

INDUSTRY PIONEERS

Improving Lives with Precision Diagnostics®

Invivoscribe is an industry pioneer with over 20 years of experience developing and manufacturing diagnostic products and reagents for leukemias and lymphomas. All of our diagnostic tests generate meaningful results allowing healthcare providers to confirm or modify treatment for each patient.

PRODUCTS

Best in class assays and reagents

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

CLINICAL LAB SERVICES

LabPMM offers clinical services with global reach

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally harmonized testing of novel and proprietary biomarkers that are critically important for patient care.

PARTNERSHIPS

CDx Turn-Key Collaboration

Invivoscribe provides a proven strategy to accelerate drug approvals, offering Product Development, Manufacturing, Clinical Lab Services and Global Regulatory Expertise.

CONNECT

Invivoscribe Newsroom

The Latest Publications, News, Articles and Press Releases

CONNECT

Invivoscribe Newsroom

The Latest Publications, News, Articles and Press Releases

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

A proven strategy to accelerate
drug approvals

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 21st, 2019
Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

August 25th, 2018
A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 22nd, 2018
Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

Improving Lives with Precision Diagnostics^®

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally harmonized testing of novel and proprietary biomarkers that are critically important for patient care.

Improving Lives with Precision Diagnostics^®

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally harmonized testing of novel and proprietary biomarkers that are critically important for patient care.

The Latest Publications, News, Articles
and Press Releases